<DOC>
	<DOCNO>NCT00147121</DOCNO>
	<brief_summary>To establish standard therapy patient advanced-stage low grade B-cell lymphoma</brief_summary>
	<brief_title>Rituximab+Standard CHOP v Rituximab+Bi-weekly CHOP Untreated Stage III/IV Low-grade B-cell Lymphoma ( JCOG0203 )</brief_title>
	<detailed_description>Since currently standard therapy untreated advanced-stage low-grade B-cell lymphoma , Phase 2/3 study plan . Comparison ( ) : An intensified bi-weekly version shorten interval rituximab CHOP therapy use G-CSF , compare tri-weekly R-CHOP regimen .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Histological confirm , lowgrade Bcell lymphoma except mantle cell lymphoma histologic transformation DLBCL 2 . CD20positive 3 . Ann Arbor CS III IV 4 . Lymphoma cell count PBâ‰¦10,000/mm3 5 . 20 &lt; =age &lt; =69 6 . ECOG PS 02 7 . Bidimensionally measurable disease &gt; 1.5cm single dimension CT scan 8 . No prior chemotherapy , radiotherapy , interferonalfa , antibody therapy 9 . Normal BM , hepatic , renal , cardiac , pulmonary function 10 . Written inform consent 1 . CNS involvement 2 . Glaucoma 3 . DM treat insulin 4 . Uncontrollable HT 5 . AP , AMI 6 . Positive HBs antigen 7. seropositive HCV 8. seropositive HIV 9 . Interstitial pneumonitis , pulmonary fibrosis , emphysema 10 . Severe infection 11 . Liver cirrhosis 12 . Double cancer 13 . Pregnant lactate 14 . Patients desire auto PBST CR 15 . Patients treat major tranquilizer antidepressant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>CHOP</keyword>
	<keyword>Bi-weekly</keyword>
	<keyword>low-grade B-cell lymphoma</keyword>
	<keyword>advanced stage</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Untreated stage III/IV low-grade B-cell lymphoma</keyword>
</DOC>